Seven Day Primaquine Treatment Is Safe, Noninferior to 14 Day Course
In patients with malaria who have normal levels of glucose-6-phosphate dehydrogenase, 7-day primaquine was well tolerated and noninferior to 14-day primaquine.
Vector-borne Disease
FDA Clears New Testing Algorithm for Lyme Disease Diagnosis
The FDA has cleared for marketing the ZEUS Borrelia Modified Two-Tiered Testing algorithm to help in the diagnosis of Lyme disease.
Diagnostics in Patients At Risk for Both Dengue and Zika Infection
The CDC has summarized present and updated guidelines on dengue and Zika virus diagnostic testing in patients with a clinically compatible illness who live in or recently traveled to an endemic area.
Emerging Tickborne Illnesses: Beyond Lyme Disease
Although most providers are familiar with the symptoms of Lyme disease, coinfection with other tickborne illnesses such as babesiosis, human granulocytic anaplasmosis, and human monocytic ehrlichiosis is possible and becoming more prevalent.
Lyme Disease Risk in an Urban Center in New York City
In an investigation of Lyme disease risk in the urban setting of New York City, forest parks with vegetated buffers and increased connectivity had higher Ixodes scapularis nymph densities, and the degree of connectivity strongly determined Borrelia burgdorferi nymphal infection prevalence, according to data published in Emerging Infectious Diseases. Because most tickborne disease studies in…
Malaria Incidence Higher Among African Travelers Returning to France
Significant changes may have occurred in France, in the population that developed malaria after travel in endemic areas, which implies that preventative strategies need to be adapted.
Treatment for Severe Malaria Receives Breakthrough Therapy Status
The Food and Drug Administration has granted an investigational treatment for severe malaria Breakthrough Therapy designation.
Reported Cases of Spotted Fever Rickettsiosis Rarely Confirmed
Only 1.0 percent of reported cases of spotted fever rickettsioses (SFR) meet the confirmed case definition.
Neurologic Manifestations of Zika Virus Infection: What We Know So Far
Jonathan Miner, MD, PhD, and Karin Nielsen-Saines, MD, MPH, discuss the latest insights about neurologic complications of ZVI and knowledge gaps that still exist in this field.
Dengue Vaccine Candidate TAK-003 Looks Promising in Phase 3 Trial
The TIDES trial is investigating the safety and efficacy of 2 doses of TAK-003 in preventing dengue fever caused by any of the 4 dengue virus serotypes.
Next post in Vector-borne Illnesses
